BURLINGTON, Mass., Dec. 20, 2011 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc., (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, today announced that Karin Hehenberger, M.D., Ph.D. has joined the Company as Senior Vice President of Scientific Affairs. Dr. Hehenberger’s responsibilities will initially be focused on broadening the scope of proof of concept trials in various autoimmune diseases with Coronado’s lead product CNDO-201.
